SEC Form S-8 filed by Rapport Therapeutics Inc.
As filed with the Securities and Exchange Commission on March 10, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Rapport Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
88-0724208 |
(State or other jurisdiction of |
(I.R.S. Employer |
Rapport Therapeutics, Inc. 99 High Street, Suite 2100 Boston, MA (Address of Principal Executive Offices) |
02110 (Zip Code)
|
Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan
(Full title of the plan)
Abraham N. Ceesay, M.B.A.
Chief Executive Officer
99 High Street, Suite 2100
Boston, MA 02110
(Name and address of agent for service)
(857) 321-8020
(Telephone number, including area code, of agent for service)
Copies to:
Kingsley L. Taft
Stephanie A. Richards
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Rapport Therapeutics, Inc. (the “Registrant”) for the purpose of registering 2,388,628 additional shares of common stock, par value $0.001 per share (“Common Stock”), under the Registrant’s 2024 Stock Option and Incentive Plan (the “2024 Plan”), which were added on January 1, 2026 as a result of an automatic annual increase provision therein.
These additional shares are of the same class as other securities relating to the 2024 Plan for which the Registrant’s registration statement on Form S-8, filed with the Securities and Exchange Commission on June 7, 2024 (File No. 333-280058) and March 11, 2025 (File No. 333-285697), are effective (the “Earlier Registration Statements”).
Pursuant to General Instruction E to Form S-8 regarding registration of additional securities, the contents of the Earlier Registration Statements, except for “Item 8. Exhibits”, are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Earlier Registration Statements are presented herein.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
|
4.1 |
|
|
|
|
|
4.2 |
|
|
|
|
|
4.3 |
|
|
|
|
|
5.1* |
|
|
|
|
|
23.1* |
|
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. |
|
|
|
23.2* |
|
|
|
|
|
24.1* |
|
Power of Attorney (included on signature page). |
|
|
|
99.1 |
|
|
|
|
|
107* |
|
|
* Filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Massachusetts, on this 10th day of March, 2026.
|
|
RAPPORT THERAPEUTICS, INC. |
|
|
|
|
|
|
|
By: |
/s/ Abraham N. Ceesay |
|
|
|
Name: Abraham N. Ceesay, M.B.A. |
|
|
|
Title: Chief Executive Officer |
|
|
|
|
POWER OF ATTORNEY AND SIGNATURES
Each individual whose signature appears below hereby constitutes and appoints each of Abraham N. Ceesay, M.B.A. and Troy Ignelzi as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
Date |
|
|
|
|
/s/ Abraham N. Ceesay |
|
Chief Executive Officer and Director |
March 10, 2026 |
Abraham N. Ceesay, M.B.A. |
|
(Principal Executive Officer) |
|
|
|
|
|
/s/ Troy Ignelzi |
|
Chief Financial Officer |
March 10, 2026 |
Troy Ignelzi |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
/s/ Steven M. Paul |
|
Director and Chairman |
March 10, 2026 |
Steven M. Paul, M.D. |
|
|
|
|
|
|
|
/s/ James I. Healy |
|
Director |
March 10, 2026 |
James I. Healy, M.D., Ph.D. |
|
|
|
|
|
|
|
/s/ John Maraganore |
|
Director |
March 10, 2026 |
John Maraganore, Ph.D. |
|
|
|
|
|
|
|
/s/ Paul Silva |
|
Director |
March 10, 2026 |
Paul Silva |
|
|
|
|
|
|
|
/s/ Raymond Sanchez |
|
Director |
March 10, 2026 |
Raymond Sanchez, M.D. |
|
|
|
|
|
|
|
/s/ Robert J. Perez |
|
Director |
March 10, 2026 |
Robert J. Perez |
|
|
|
|
|
|
|
/s/ Reid Huber |
|
Director |
March 10, 2026 |
Reid Huber, Ph.D. |
|
|
|
|
|
|
|
/s/ Wendy B. Young |
|
Director |
March 10, 2026 |
Wendy B. Young, Ph.D. |
|
|
|
|
|
|
|